全文获取类型
收费全文 | 9227篇 |
免费 | 1119篇 |
国内免费 | 694篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 84篇 |
妇产科学 | 73篇 |
基础医学 | 917篇 |
口腔科学 | 160篇 |
临床医学 | 1273篇 |
内科学 | 1332篇 |
皮肤病学 | 74篇 |
神经病学 | 449篇 |
特种医学 | 296篇 |
外国民族医学 | 6篇 |
外科学 | 918篇 |
综合类 | 1887篇 |
现状与发展 | 3篇 |
一般理论 | 1篇 |
预防医学 | 772篇 |
眼科学 | 169篇 |
药学 | 1028篇 |
13篇 | |
中国医学 | 686篇 |
肿瘤学 | 815篇 |
出版年
2024年 | 36篇 |
2023年 | 193篇 |
2022年 | 369篇 |
2021年 | 620篇 |
2020年 | 455篇 |
2019年 | 359篇 |
2018年 | 383篇 |
2017年 | 319篇 |
2016年 | 288篇 |
2015年 | 448篇 |
2014年 | 577篇 |
2013年 | 522篇 |
2012年 | 697篇 |
2011年 | 720篇 |
2010年 | 487篇 |
2009年 | 369篇 |
2008年 | 441篇 |
2007年 | 447篇 |
2006年 | 443篇 |
2005年 | 457篇 |
2004年 | 340篇 |
2003年 | 362篇 |
2002年 | 271篇 |
2001年 | 235篇 |
2000年 | 216篇 |
1999年 | 205篇 |
1998年 | 126篇 |
1997年 | 116篇 |
1996年 | 79篇 |
1995年 | 94篇 |
1994年 | 74篇 |
1993年 | 41篇 |
1992年 | 49篇 |
1991年 | 35篇 |
1990年 | 47篇 |
1989年 | 26篇 |
1988年 | 16篇 |
1987年 | 17篇 |
1986年 | 26篇 |
1985年 | 13篇 |
1984年 | 4篇 |
1983年 | 7篇 |
1982年 | 2篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1973年 | 1篇 |
1963年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 96 毫秒
1.
目的 通过网络药理学的方法进行预测,再深一步进行动物实验验证来研究柴胡疏肝散治疗CAG的作用机制。方法 首先在TCMSP数据库中检索柴胡疏肝散的所有活性成分与药物靶点;通过收集PharmGkb、OMIM、GeneCards和DrugBank数据库中收录的慢性萎缩性胃炎的相关靶点。将药物靶点与疾病靶点进行映射筛选出交集靶点,将得到的交集靶点构建PPI网络与活性成分-共同靶点网络,并对其进行GO和KEGG富集分析。最后利用Vina软件进行分子对接实验验证,并通过免疫印迹法验证柴胡疏肝散对两种受体蛋白EGFR和STAT1的影响。结果 最终筛选得到柴胡疏肝散活性成分104个,潜在靶点238个,与慢性萎缩性胃炎的交集靶点52个;GO与KEGG富集分析分别得到2166条目和148条目,主要涉及到JAK-STAT信号通路、TNF信号通路、HIF-1信号通路等;分子对接结果显示EGFR、STAT1两个靶点能够与核心活性成分能够自发结合成较为稳定的构像;免疫印迹法实验证明柴胡疏肝散能够降低大鼠胃黏膜组织EGFR和STAT1蛋白表达。结论 通过网络药理学和实验验证,发现柴胡疏肝散可能通过调节EGFR和STAT1蛋白表达来共同调控胃黏膜细胞增殖与凋亡,进而发挥着治疗慢性萎缩性胃炎的效果,为深入进行柴胡疏肝散治疗慢性萎缩性胃炎的作用机制研究提供新思路和新方法。 相似文献
2.
Zhenzhen Zhang Mark Garzotto Tomasz M. Beer Philippe Thuillier Stephen Lieberman Motomi Mori 《Nutrition and cancer》2016,68(8):1309-1319
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue. 相似文献
3.
4.
人类微生物群是由寄生在人体上皮屏障的细菌和其他微生物组成的,其中大部分位于肠道内,与宿主之间形成共生的关系。机体肠道微生物的组成虽然受到年龄、饮食、生活方式等因素的影响,但在正常生理情况下是相对稳定的。近年来,肠道菌群与恶性肿瘤的关系越来越受到重视。肠道菌群不但能够维持局部稳态,还能调节机体代谢、炎症和免疫等生理过程。有研究表明,微生物群,特别是肠道菌群能够显著调节机体对癌症治疗的反应性以及机体对毒副反应的敏感性。检查肠道菌群中各菌种之间的比例可作为筛查恶性肿瘤的新方法。本文将综述微生物群具有影响肿瘤的发生发展、抗肿瘤治疗疗效以及药物不良反应的证据,以及其中所涉及的微生物种类,从而为恶性肿瘤精准治疗提供证据。 相似文献
5.
安息香为安息香科白花树Styrax tonkinensis (Pierre) Craib ex Hart.的干燥树脂,主要化学成分为香脂酸类和三萜类物质,及少数木脂素类物质,其中香脂酸类化合物是其主要活性成分。安息香主要药理活性有抗炎解热、抗肿瘤、血脑屏障保护等。本文对安息香药材的化学成分和药理作用进行了综述,并从多角度分析预测了安息香可能的质量标志物,为安息香药材的质量控制、合理开发与利用提供参考。 相似文献
6.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
7.
8.
9.
Mei Zhan 《Medical anthropology》2016,35(3):247-262
ABSTRACTIn this article, I discuss recent experiments in ‘classical’ (gudian) Chinese medicine. As the marketization and privatization of health care deepens and enters uncharted territories in China, a cohort of young practitioners and entrepreneurs have begun their quest for the ‘primordial spirit’ of traditional Chinese medicine by setting up their own businesses where they engage in clinical, pedagogical, and entrepreneurial practices outside of state-run institutions. I argue that these explorations in classical Chinese medicine, which focus on classical texts and Daoist analytics, do not aim to restore spirituality to the scientized and secularized theory of traditional Chinese medicine. Nor are they symptomatic of withdrawals from the modern world. Rather, these ‘cosmic experiments’ need to be understood in relation to dialectical and historical materialisms as modes of knowledge production and political alliance. In challenging the status of materialist theory and the process of theorization in traditional Chinese medicine and postsocialist life more broadly speaking, advocates of classical Chinese medicine imagine nondialectical materialisms as immanent ways of thinking, doing, and being in the world. 相似文献
10.
电子医疗数据已成为大数据时代开展药品安全主动监测的重要资源。基于此确认药品与不良事件是否存在关联,要回归传统的流行病学研究设计,选取恰当的对照进行对比。本文主要阐述不同对照选取的原理、适用情形,介绍、评价并比较各种对照选取的思路与参数,引入对照选择批量化实现的进展性成果,以期为我国利用电子医疗数据开展上市后药品安全性监测提供方法学参考。 相似文献